NeuroPace Stock (NASDAQ:NPCE)
Previous Close
$10.64
52W Range
$5.45 - $18.15
50D Avg
$8.53
200D Avg
$9.01
Market Cap
$341.46M
Avg Vol (3M)
$81.69K
Beta
1.80
Div Yield
-
NPCE Company Profile
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.
NPCE Performance
Peer Comparison
| Ticker | Company |
|---|---|
| FNA | Paragon 28, Inc. |
| ANIK | Anika Therapeutics, Inc. |
| OFIX | Orthofix Medical Inc. |
| ITGR | Integer Holdings Corporation |
| LUNG | Pulmonx Corporation |
| SRDX | Surmodics, Inc. |
| NVRO | Nevro Corp. |
| KIDS | OrthoPediatrics Corp. |
| GKOS | Glaukos Corporation |
| IRMD | IRadimed Corporation |
| AORT | Artivion, Inc. |
| CVRX | CVRx, Inc. |
| CNMD | CONMED Corporation |